People | February 20, 2022
Resolution Therapeutics strengthens its team with two new appointments
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Recall does not include any metabolic deficiency nutrition formulas
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Subscribe To Our Newsletter & Stay Updated
